{"id":"NCT02258542","sponsor":"AstraZeneca","briefTitle":"A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA","officialTitle":"A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-19","primaryCompletion":"2017-10-18","completion":"2018-07-02","firstPosted":"2014-10-07","resultsPosted":"2019-02-06","lastUpdate":"2019-08-21"},"enrollment":2133,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"OTHER"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]}],"arms":[{"label":"Benralizumab Arm A","type":"EXPERIMENTAL"},{"label":"Benralizumab Arm B","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.","primaryOutcome":{"measure":"Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients","timeFrame":"Week 56","effectByArm":[{"arm":"SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks","deltaMin":-0.005,"sd":0.0223},{"arm":"SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks","deltaMin":-0.005,"sd":0.0239},{"arm":"ZONDA - Benralizumab 30 mg q.4 Weeks","deltaMin":-0.007,"sd":0.0283},{"arm":"ZONDA - Benralizumab 30 mg q.8 Weeks","deltaMin":-0.005,"sd":0.0244}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":429,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","Chile","Czechia","France","Germany","Japan","Peru","Philippines","Poland","Romania","Russia","South Africa","South Korea","Spain","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["33609624","30416083"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2560&filename=D3250C00021_Revised_CSP_3_16Dec2016_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2560&filename=D3250C00021_SAP_Edition_3_11_Dec2017_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2560&filename=BORA_clinical_study_protocol-redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":102,"n":783},"commonTop":["Viral upper respiratory tract infection","Asthma","Upper respiratory tract infection","Bronchitis","Headache"]}}